AQST
Aquestive Therapeutics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+13/100
Last price
4.61
▲ 0.04 (0.88%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
4.57
Day high
4.65
Day low
4.46
Volume
1.21M
Market cap
$578.61M
P/E (TTM)
—
52W range
2.93 – 7.55
Trailing performance
Returnvs SPY
1W
-1.28%
-3.2%
1M
-13.67%
-14.8%
3M
+6.96%
+2.4%
6M
+11.62%
-6.6%
YTD
-28.64%
-42.9%
1Y
-20.52%
-36.9%
3Y
+201.31%
+119.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AQST open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+90.37K
Net buying
Buy transactions
6
232.37K shares
Sell transactions
7
142.01K shares
Net transactions
+13
Buys less sells
Sell : buy shares
0.6 : 1
Mixed
Insider-held shares
3.48M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 15, 26 | BARBER DANIEL R Chief Executive Officer |
SELL | 25.00K | $120.49K | Direct |
| Sep 9, 26 | BOYD PETER E Officer |
CONVERSION | 2.29K | $2.20K | Direct |
| Sep 9, 26 | KORCZYNSKI SHERRY Officer |
CONVERSION | 8.75K | $23.19K | Direct |
| Sep 9, 26 | KORCZYNSKI SHERRY Officer |
SELL | 8.75K | $45.67K | Direct |
| Sep 8, 26 | BARBER DANIEL R Chief Executive Officer |
CONVERSION | 91.74K | $88.07K | Direct |
| Sep 3, 26 | JUNG CASSIE Chief Operating Officer |
CONVERSION | 4.59K | $4.40K | Direct |
| Aug 17, 26 | BARBER DANIEL R Chief Executive Officer |
SELL | 25.00K | $107.17K | Direct |
| Jul 16, 26 | BARBER DANIEL R Chief Executive Officer |
SELL | 25.00K | $100.19K | Direct |
| Jun 23, 26 | KROP JULIE Director |
CONVERSION | 25.00K | $17.83K | Direct |
| Jun 23, 26 | KROP JULIE Director |
SELL | 25.00K | $125.39K | Direct |
| Jun 15, 26 | BARBER DANIEL R Chief Executive Officer |
SELL | 25.00K | $104.01K | Direct |
| May 18, 26 | ZALEWSKI THOMAS A. Officer |
STOCK | 100.00K | $0 | Direct |
| May 15, 26 | BARBER DANIEL R Chief Executive Officer |
SELL | 8.26K | $35.41K | Direct |
| Mar 10, 26 | JUNG CASSIE Chief Operating Officer |
SELL | 45.79K | $191.09K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BARBER DANIEL R |
Chief Executive Officer | 652.32K | Sale |
BOYD PETER E |
Officer | 284.02K | Conversion of Exercise of derivative security |
BRAENDER LORI J |
Officer | 442.88K | Sale |
BRATTON DOUGLAS K |
Beneficial Owner of more than 10% of a Class of Security | — | Stock Gift |
CIOFFI MELINA |
Officer | 274.87K | Sale |
JUNG CASSIE |
Chief Operating Officer | 208.83K | Conversion of Exercise of derivative security |
KORCZYNSKI SHERRY |
Officer | 235.69K | Conversion of Exercise of derivative security |
KRAUS CARL N |
Officer | 282.48K | Sale |
TOTH A ERNEST JR |
Chief Financial Officer | 376.11K | Sale |
WARGACKI STEPHEN |
Officer | 343.55K | Stock Award(Grant) |
Fundamentals
Market cap$578.61M
Enterprise value$539.15M
Revenue (TTM)$54.09M
Gross profit$36.26M
EBITDA$-52.20M
Net income$-78.23M
EPS (TTM)$-0.66
Free cash flow$-26.89M
Total cash$98.49M
Total debt$59.03M
Book value / share$-0.45
Shares outstanding125.51M
Float114.61M
Short % of float22.65%
Dividend yield0.00%
Beta (5Y)1.49
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.09
PEG ratio—
Price / sales—
Price / book—
EV / revenue9.97
EV / EBITDA-10.33
Gross margin67.04%
Operating margin-59.51%
Profit margin-144.63%
Return on equity—
Return on assets-29.20%
Debt / equity—
Current ratio7.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $44.55M | $57.56M | $50.58M | $47.68M | -22.6% |
| Operating revenue | $44.55M | $57.56M | $50.58M | $47.68M | -22.6% |
| Cost of revenue | $18.55M | $17.87M | $20.83M | $19.39M | +3.8% |
| Gross profit | $25.99M | $39.69M | $29.75M | $28.29M | -34.5% |
| Research & development | $17.19M | $20.28M | $13.10M | $17.48M | -15.2% |
| Selling, general & admin | $79.85M | $50.18M | $31.75M | $52.88M | +59.1% |
| Total operating expense | $97.04M | $70.46M | $44.85M | $70.36M | +37.7% |
| Operating income | -$71.05M | -$30.77M | -$15.10M | -$42.07M | -130.9% |
| Net interest income | -$12.73M | -$13.38M | $8.86M | -$12.34M | +4.8% |
| Pre-tax income | -$83.78M | -$44.15M | -$7.63M | -$54.41M | -89.8% |
| Tax provision | $0 | -$14.00K | $245.00K | $0 | +100.0% |
| Net income | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -89.8% |
| Net income to common | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -89.8% |
| Basic EPS | -0.78 | -0.51 | -0.13 | -1.12 | -52.9% |
| Diluted EPS | -0.78 | -0.51 | -0.13 | -1.12 | -52.9% |
| EBIT | -$66.68M | -$27.33M | -$163.00K | -$41.97M | -144.0% |
| EBITDA | -$66.14M | -$26.62M | $1.18M | -$39.58M | -148.5% |
| Basic shares | 106.93M | 86.73M | 61.26M | 48.73M | +23.3% |
| Diluted shares | 106.93M | 86.73M | 61.26M | 48.73M | +23.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $121.17M | $71.55M | $23.87M | $27.27M | — | +69.4% |
| Cash & short-term investments | $121.17M | $71.55M | $23.87M | $27.27M | — | +69.4% |
| Accounts receivable | $8.01M | $4.92M | $5.57M | $3.27M | — | +62.9% |
| Inventory | $6.17M | $6.04M | $6.77M | $5.78M | — | +2.1% |
| Total current assets | $149.27M | $88.22M | $40.97M | $39.89M | — | +69.2% |
| Property, plant & equipment | $8.51M | $8.98M | $9.74M | $9.30M | — | -5.2% |
| Goodwill & intangibles | — | $0 | $1.28M | $1.44M | $51.00K | — |
| Total assets | $160.43M | $101.42M | $57.42M | $57.07M | — | +58.2% |
| Total current liabilities | $47.61M | $18.86M | $18.31M | $39.53M | — | +152.4% |
| Current debt | $9.99M | $26.00K | $22.00K | $18.70M | — | +38,338.5% |
| Long-term debt | $27.52M | $32.50M | $27.51M | $33.45M | — | -15.3% |
| Total debt | $42.48M | $38.00M | $33.32M | $57.49M | — | +11.8% |
| Total liabilities | $194.09M | $161.58M | $163.91M | $175.62M | — | +20.1% |
| Retained earnings | -$447.00M | -$363.21M | -$319.08M | -$311.21M | — | -23.1% |
| Shareholder equity | -$33.66M | -$60.16M | -$106.49M | -$118.55M | — | +44.0% |
| Working capital | $101.66M | $69.36M | $22.66M | $360.00K | — | +46.6% |
| Net tangible assets | -$33.66M | -$60.16M | -$107.77M | -$119.99M | — | +44.0% |
| Shares issued | 122.04M | 91.41M | 68.53M | 54.83M | — | +33.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$83.78M | -$44.14M | -$7.87M | -$54.41M | -89.8% |
| Depreciation & amortisation | $548.00K | $718.00K | $1.34M | $2.39M | -23.7% |
| Stock-based compensation | $7.62M | $7.10M | $2.69M | $4.38M | +7.4% |
| Change in working capital | $12.18M | -$9.96M | -$5.34M | $31.98M | +222.4% |
| Operating cash flow | -$52.43M | -$35.76M | -$6.38M | -$9.82M | -46.6% |
| Capital expenditure | -$562.00K | -$159.00K | -$995.00K | -$2.52M | -253.5% |
| Investing cash flow | -$562.00K | -$159.00K | -$995.00K | -$2.52M | -253.5% |
| Financing cash flow | $102.62M | $83.59M | $3.97M | $11.59M | +22.8% |
| Free cash flow | -$52.99M | -$35.92M | -$7.38M | -$12.34M | -47.5% |
| End cash position | $121.17M | $71.55M | $23.87M | $27.27M | +69.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $13.82M | $14.45M | $13.02M | $12.81M | $10.00M | -4.3% |
| Operating revenue | $13.82M | $14.45M | $13.02M | $12.81M | $10.00M | -4.3% |
| Cost of revenue | $4.02M | $3.47M | $5.84M | $4.51M | $4.56M | +15.8% |
| Gross profit | $9.80M | $10.98M | $7.18M | $8.30M | $5.44M | -10.7% |
| Research & development | $3.96M | $4.20M | $3.20M | $4.53M | $4.11M | -5.8% |
| Selling, general & admin | $14.06M | $10.98M | $32.82M | $15.25M | $12.71M | +28.1% |
| Total operating expense | $18.02M | $15.18M | $36.02M | $19.78M | $16.81M | +18.7% |
| Operating income | -$8.22M | -$4.20M | -$28.84M | -$11.48M | -$11.37M | -95.6% |
| Net interest income | -$2.96M | -$3.85M | -$3.02M | -$3.97M | -$2.18M | +23.2% |
| Pre-tax income | -$22.86M | -$8.06M | -$31.86M | -$15.45M | -$13.55M | -183.8% |
| Net income | -$22.86M | -$8.06M | -$31.86M | -$15.45M | -$13.55M | -183.8% |
| Net income to common | -$22.86M | -$8.06M | -$31.86M | -$15.45M | -$13.55M | -183.8% |
| Basic EPS | -0.18 | -0.07 | -0.26 | -0.14 | -0.14 | -157.1% |
| Diluted EPS | -0.18 | -0.07 | -0.26 | -0.14 | -0.14 | -157.1% |
| EBIT | -$19.02M | -$4.12M | -$27.59M | -$11.17M | -$9.27M | -361.6% |
| EBITDA | -$18.89M | -$4.01M | -$27.46M | -$11.03M | -$9.13M | -371.3% |
| Basic shares | 124.99M | 122.61M | 121.97M | 110.58M | 99.33M | +1.9% |
| Diluted shares | 124.99M | 122.61M | 121.97M | 110.58M | 99.33M | +1.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $98.49M | $110.73M | $121.17M | $129.06M | $60.54M | — | -11.1% |
| Cash & short-term investments | $98.49M | $110.73M | $121.17M | $129.06M | $60.54M | — | -11.1% |
| Accounts receivable | $7.72M | $5.26M | $8.01M | $9.48M | $9.65M | — | +46.7% |
| Inventory | $7.37M | $8.07M | $6.17M | $7.88M | $8.13M | — | -8.7% |
| Total current assets | $118.49M | $130.18M | $149.27M | $151.67M | $81.72M | — | -9.0% |
| Property, plant & equipment | $11.91M | $8.31M | $8.51M | $8.69M | $8.77M | — | +43.4% |
| Goodwill & intangibles | — | — | — | $0 | $0 | $0 | — |
| Total assets | $132.10M | $141.13M | $160.43M | $163.56M | $93.70M | — | -6.4% |
| Total current liabilities | $16.48M | $31.75M | $47.61M | $25.57M | $23.16M | — | -48.1% |
| Current debt | $32.00K | $13.66M | $9.99M | $6.33M | $3.18M | — | -99.8% |
| Long-term debt | $50.65M | $25.10M | $27.52M | $29.94M | $31.84M | — | +101.8% |
| Total debt | $59.03M | $43.58M | $42.48M | $41.38M | $40.26M | — | +35.5% |
| Total liabilities | $188.69M | $175.18M | $194.09M | $167.67M | $166.29M | — | +7.7% |
| Retained earnings | -$477.92M | -$455.06M | -$447.00M | -$415.14M | -$399.69M | — | -5.0% |
| Shareholder equity | -$56.59M | -$34.05M | -$33.66M | -$4.11M | -$72.59M | — | -66.2% |
| Working capital | $102.02M | $98.43M | $101.66M | $126.10M | $58.57M | — | +3.6% |
| Net tangible assets | -$56.59M | -$34.05M | -$33.66M | -$4.11M | -$72.59M | — | -66.2% |
| Shares issued | 125.51M | 124.28M | 122.04M | 121.66M | 99.35M | — | +1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$22.86M | -$8.06M | -$31.86M | -$15.45M | -$13.55M | -183.8% |
| Depreciation & amortisation | $136.00K | $113.00K | $130.00K | $139.00K | $140.00K | +20.4% |
| Stock-based compensation | $2.90M | $2.32M | $1.38M | $2.78M | $1.88M | +24.9% |
| Change in working capital | -$3.10M | -$12.39M | $19.14M | -$2.88M | $919.00K | +75.0% |
| Operating cash flow | -$9.44M | -$14.81M | -$8.47M | -$12.65M | -$7.91M | +36.2% |
| Capital expenditure | -$212.00K | -$52.00K | -$85.00K | -$235.00K | -$107.00K | -307.7% |
| Investing cash flow | -$212.00K | -$52.00K | -$85.00K | -$235.00K | -$107.00K | -307.7% |
| Financing cash flow | -$2.59M | $4.42M | $660.00K | $81.41M | -$100.00K | -158.6% |
| Free cash flow | -$9.65M | -$14.86M | -$8.55M | -$12.88M | -$8.02M | +35.0% |
| End cash position | $98.49M | $110.73M | $121.17M | $129.06M | $60.54M | -11.1% |
Options analytics
Put / call volume
0.24
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
4.00
-13.2% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
1.03K
Contracts, this expiry
Put volume
252
Contracts, this expiry
Heaviest call OI
4.00
0 contracts
Heaviest put OI
4.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.12 | -0.07 | +45.7% |
| Mar 2026 | -0.13 | -0.05 | +64.7% |
| Dec 2025 | -0.12 | -0.14 | -18.1% |
| Sep 2025 | -0.11 | -0.11 | -4.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.14 | 2 | $11.02M | -14.0% |
| Next quarter | -0.14 | 2 | $10.63M | -18.3% |
| Current year | -0.45 | 2 | $49.93M | +12.1% |
| Next year | -0.57 | 2 | $67.77M | +35.7% |
Analyst targets & ownership
Mean target$9.33
High target$11.00
Low target$6.00
Implied upside102.46%
Analyst count9
ConsensusNONE
Strong buy / Buy2 / 7
Hold0
Sell / Strong sell0 / 0
Held by insiders2.77%
Held by institutions58.39%
Institutions holding240
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.64
-0.69% from price
SMA 20
4.74
-2.79% from price
SMA 50
4.59
+0.38% from price
SMA 100
4.38
+5.22% from price
SMA 200
4.33
+6.50% from price
EMA 12
4.66
-1.05% from price
EMA 26
4.71
-2.07% from price
EMA 50
4.63
-0.38% from price
RSI (14)
46.6
Neutral
MACD (12,26,9)
-0.05
Hist -0.04
ATR (14)
0.22
4.80% of price
Realised vol 30D
47.0%
Annualised
Bollinger upper
5.07
20, 2σ
Bollinger lower
4.42
20, 2σ
50 / 200 cross
Golden
4.59 vs 4.33
Trend bias
Above 200
+6.50%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.85
Less volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
47.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-60.6%
Peak to trough
Max drawdown 5Y
-90.1%
Peak to trough
ATR 14
0.22
4.80% of price
Beta (reported)
1.49
5Y monthly, from filing
Short interest
Shares short
27.16M
Prior 20.95M
Change vs prior
+29.6%
Shorts adding
% of float
22.65%
Heavily shorted
% of shares out
21.64%
Against total outstanding
Days to cover
9.1
Crowded exit
Float
114.61M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 7, 25 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Oct 9, 25 | JMP Securities | MAINTAINED | Market Outperform | Market Outperform |
| Sep 8, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Jun 17, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 15, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 2, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 10, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 7, 25 | Lake Street | MAINTAINED | Buy | Buy |
| Dec 20, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 17, 24 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Nov 11, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-29
Corporate Changes & Voting Matters
8-K · 2026-09-25
Corporate Changes & Voting Matters
8-K · 2026-09-17
Corporate Changes & Voting Matters
8-K · 2026-08-11
Corporate Changes & Voting Matters
8-K · 2026-08-10
Offering Registrations
S-3 · 2026-06-26
Corporate Changes & Voting Matters
8-K · 2026-06-10
Corporate Changes & Voting Matters
8-K · 2026-05-13
Headlines
Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
GlobeNewswire · 8d ago
Aquestive Therapeutics Resubmits Anaphylm NDA to FDA
MT Newswires · 20d ago
Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
GlobeNewswire · 20d ago
Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
Insider Monkey · 29d ago
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire · 36d ago
Aquestive (AQST) Q2 2026 Earnings Call Transcript
Motley Fool · 49d ago
Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ...
GuruFocus.com · 55d ago
Aquestive Therapeutics Q2 Earnings Call Highlights
MarketBeat · 56d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.